Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study.
Atopic dermatitis
Burden of disease
Comorbidities
Cost-of-illness model
Healthcare resource utilisation
Mild-to-moderate
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
08
02
2021
accepted:
24
03
2021
pubmed:
14
4
2021
medline:
14
4
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
The burden of mild-to-moderate atopic dermatitis (AD) in the United Kingdom (UK) is not well understood. Long-lasting AD flares may lead to systemic inflammation resulting in reversible progression from mild to more severe AD. This study aimed to assess the clinical and economic burden of mild-to-moderate AD in the UK. AD patients were identified in the Health Improvement Network (THIN) from 2013 to 2017 and propensity score matched to non-AD controls by demographics. Patients were identified based on continuous disease activity using validated algorithms and sufficient patient status to fully validate data integrity for the entire period. Mild-to-moderate AD patients were identified by using treatment as a surrogate. Demographics, clinical characteristics and healthcare resource use (HCRU) were obtained from THIN. Literature reviews were conducted to obtain additional outcomes. A cost-of-illness model was developed to extrapolate the burden in 2017 to the UK population and in subsequent years (2018-2022). In 2017, the prevalence of mild-to-moderate AD in THIN was 1.28%. These patients reported higher comorbidity rates and significantly higher (p < 0.0001) HCRU, encompassing mean general practitioner visits (5.57 versus 3.59), AD-related prescriptions (5.85 versus 0.68) and total referrals (0.97 versus 0.82) versus matched non-AD controls. The model projected total HCRU and drug excess costs of €462.99M over the 5 years. The excess cost decreased to €417.35M after excluding patients on very potent topical corticosteroids, who most likely had at least moderate disease. The excess costs increased to €1.21B and €7.06B when considering comorbidity burden and productivity losses, respectively. Mild-to-moderate AD patients had higher comorbidity burden, HCRU and cost compared with matched non-AD controls. Overall, UK country-based economic burden was high given partly the high prevalence of this disease. Moreover, productivity burden and comorbidities had considerable impact on the economic burden, which further suggests the importance of optimal disease management.
Identifiants
pubmed: 33846907
doi: 10.1007/s13555-021-00519-7
pii: 10.1007/s13555-021-00519-7
pmc: PMC8163940
doi:
Types de publication
Journal Article
Langues
eng
Pagination
907-928Références
Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–22.
pubmed: 26377142
Deckers IA, McLean S, Linssen S, Mommers M, Van Schayck C, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PloS one. 2012;7(7):e39803.
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson E, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93.
pubmed: 29319189
Abuabara K, Ye M, McCulloch CE, Sullivan A, Margolis DJ, Strachan DP, et al. Clinical onset of atopic eczema: Results from 2 nationally representative British birth cohorts followed through midlife. J Allergy Clin Immunol. 2019;144(3):710–9.
pubmed: 31260715
pmcid: 6721832
Schofield J, Fleming D, Grindlay D, Williams H. Skin conditions are the commonest new reason people present to general practitioners in England and Wales. Br J Dermatol. 2011;165(5):1044–50.
pubmed: 21692764
Charman CRWH. Epidemiology. In: Bieber T, Leung DYM, editors. Atopic dermatitis. New York: Dekker; 2002. p. 21–42.
Eichenfield LF, Boguniewicz M, Simpson EL, Russell JJ, Block JK, Feldman SR, et al. Translating atopic dermatitis management guidelines into practice for primary care providers. Pediatrics. 2015;136(3):554–65.
pubmed: 26240216
Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J. Dermatol. Treat. 2019;31(8):801–9.
National Eczema Society. Treating eczema – a stepped approach 2020. https://eczema.org/information-and-advice/treatments-for-eczema/ . Accessed Apr 2020.
National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management 2007. https://www.nice.org.uk/guidance/cg57/chapter/1-Guidance . Accessed Apr 2020.
National Institute for Health Care and Excellence. Tacrolimus and pimecrolimus for atopic eczema. Technology appraisal guidance [TA82]. 2004. https://www.nice.org.uk/guidance/ta82/chapter/4-Evidence-and-interpretation . Accessed Apr 2020.
National Eczema Society. Topical corticosteroids factsheet. 2019. https://www.eczema.org/documents/578 . Accessed Apr 2020.
Van Halewijn KF, Bohnen AM, Van Den Berg PJ, Pasmans SG, Bindels PJ, Elshout G. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial. BMJ open. 2019;9(6):e027239.
Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–31.
pubmed: 15131576
Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428–33.
pubmed: 23245818
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.
pubmed: 25521458
pmcid: 4378256
Schmitt J, Schwarz K, Baurecht H, Hotze M, Folster-Holst R, Rodriguez E, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–6.
pubmed: 26253344
Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014:354250.
Dharma C, Lefebvre D, Tran M, Lou W, Subbarao P, Becker A, et al. Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: effects on allergic diseases. Clin Exp Allergy. 2018;48(1):48–59.
pubmed: 29143385
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–51.
pubmed: 31034875
Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721-8.e6.
pubmed: 25579484
Ascott A, Mansfield K, Schonmann Y, Mulick A, Abuabara K, Roberts A, et al. Atopic eczema and obesity: a population‐based study. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19597 .
Huang A, Cho C, Leung DY, Brar K. Atopic dermatitis: early treatment in children. Curr TreatOpt Allergy. 2017;4(3):355–69.
Senra M, Wollenberg A. Psychodermatological aspects of atopic dermatitis. Br J Dermatol. 2014;170:38–43.
pubmed: 24930567
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.
pubmed: 28606711
Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard F, Evers A, et al. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2017;31(9):1429–39.
pubmed: 28426906
Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in europe: analysis of a cross-sectional survey. Dermatol Therapy. 2021;11(1):117–30.
Ariëns LF, Van Nimwegen KJ, Shams M, de Bruin DT, Van der Schaft J, Van Os-Medendorp H, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9–10):762–8.
pubmed: 31073619
Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the united states: analysis of healthcare claims data in the commercial, medicare, and medical databases. Adv Ther. 2017;34(8):1989–2006.
pubmed: 28707285
pmcid: 5565673
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.
pubmed: 29273118
Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–32.
pubmed: 16815160
Domínguez-Hüttinger E, Christodoulides P, Miyauchi K, Irvine AD, Okada-Hatakeyama M, Kubo M, et al. Mathematical modeling of atopic dermatitis reveals “double-switch” mechanisms underlying 4 common disease phenotypes. J Allergy Clin Immunol. 2017;139(6):1861-72. e7.
pubmed: 27931974
Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5.
pubmed: 22828580
Lo Re III, V, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. . Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf. 2009;18(9):807–14.
pubmed: 19551699
UCL. Identifying and appraising promising sources of UK clinical, health and social care data for use by NICE 2016. https://eppi.ioe.ac.uk/CMS/Portals/0/PDF%20reviews%20and%20summaries/Mapping%20real%20world%20data%202016%20Kneale%20report.pdf . Accessed Apr 2020.
Abuabara K, Magyari A, McCulloch CE, Linos E, Margolis DJ, Langan SM. Prevalence of atopic eczema among patients seen in primary care: data from the health improvement network. Ann Intern Med. 2019;170(5):354–6.
pubmed: 30508419
Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76–83.
pubmed: 19065600
Silverwood RJ, Forbes HJ, Abuabara K, Ascott A, Schmidt M, Schmidt SAJ, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ (Clinical research ed). 2018;361:k1786.
PSSRU. Unit costs of health and social care. Community-based health care staff. 2018. https://www.pssru.ac.uk/pub/uc/uc2018/community-based-health-care-staff.pdf . Accessed Oct 2019.
NHS. 2017/18 reference costs and guidance 2018. https://improvement.nhs.uk/resources/reference-costs/ . Accessed Oct 2019.
British National Formulary. 2018. https://about.medicinescomplete.com/#/content/bnf/_351442497?hspl=Tacrolimus&hspl=undefined&hspl=ointment . Accessed Oct 2019.
Monthly Index of Medical Specialities. 2018. https://www.mims.co.uk/ . Accessed Oct 2019.
Office for National Statistics. 2018. Principal projection - UK population in age groups. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/datasets/tablea21principalprojectionukpopulationinagegroups . Accessed Oct 2019.
Office for National Statistics. 2018 Population estimates. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates . Accessed Oct 2019.
Office for National Statistics. Average Sterling exchange rate: Euro 2021. https://www.ons.gov.uk/economy/nationalaccounts/balanceofpayments/timeseries/thap/mret . Accessed Feb 2021.
Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26–30.
pubmed: 27616422
Pols DH, Wartna JB, Moed H, van Alphen E, Bohnen AM, Bindels PJ. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2):143–50.
pubmed: 27010253
pmcid: 4977936
Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med. 2009;102(3):108–17.
pubmed: 19297652
pmcid: 2746851
Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: a review. Pediatr Dermatol. 2019;36(1):66–71.
pubmed: 30556595
Emerson R, Williams H, Allen B. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144(3):514–22.
pubmed: 11260008
Montgomery HE, Haines A, Marlow N, Pearson G, Mythen MG, Grocott M, et al. The future of UK healthcare: problems and potential solutions to a system in crisis. Ann Oncol. 2017;28(8):1751–5.
pubmed: 28453610
Lansang P, Lara-Corrales I, Bergman JN, Hong CH, Joseph M, Kim VHD, et al. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section IV: consensus statements on the assessment and management of pediatric atopic dermatitis. J Cutan Med Surgery. 2019;23(5_suppl):32s-s39.
Alexander H, Paller A, Traidl-Hoffmann C, Beck L, De Benedetto A, Dhar S, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2020;182(6):1331–42.
pubmed: 31677162
Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, et al. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract. 2020;8(1):248-57.e16.
pubmed: 31479767
pmcid: 6947493
Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012;26:2–8.
pubmed: 23067431
Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):e239–42.
pubmed: 22621673
Patel T, Ishiuji Y, Yosipovitch G. Nocturnal itch: why do we itch at night? Acta Derm Venereol. 2007;87(4):295–8.
pubmed: 17598030
Schmitt J, Chen CM, Apfelbacher C, Romanos M, Lehmann I, Herbarth O, et al. Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus. Allergy. 2011;66(3):404–11.
pubmed: 21029113
Jeon C, Yan D, Nakamura M, Sekhon S, Bhutani T, Berger T, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Therapy. 2017;7(3):349–64.
Saunes M, Øien T, Dotterud CK, Romundstad PR, Storrø O, Holmen TL, et al. Early eczema and the risk of childhood asthma: a prospective, population-based study. BMC Pediatr. 2012;12(1):168.
pubmed: 23095804
pmcid: 3532218
von Kobyletzki LB, Bornehag C-G, Hasselgren M, Larsson M, Lindström CB, Svensson Å. Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol. 2012;12(1):11.
Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin. 2010;30(3):309–21.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.
pubmed: 27690741
Berke R, Singh A, Guralnick M. Atopic dermatitis: an overview. Am Fam Phys. 2012;86(1):35–42.
National Institute for Health and Care Excellence. Treating eczema in people over 12 [updated 2 March 2021]. https://pathways.nice.org.uk/pathways/eczema#path=view%3A/pathways/eczema/treating-eczema-in-people-over-12.xml&content=view-index . Accessed Mar 2021.
Abuabara K, Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, et al. Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK. J Investig Dermatol. 2017;137(8):1655–62.
pubmed: 28428130
McLaughlin JC, Hamilton K, Kipping R. Epidemiology of adult overweight recording and management by UK GPs: a systematic review. Br J Gen Pract. 2017;67(663):e676–83.
pubmed: 28847775
pmcid: 5604831